At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Post-Mkt 10-21 16:00:24 EDT
1.15
+0.01
+0.88%
盘后1.15
+0.000.00%
16:00 EDT
High1.18
Low1.14
Vol20.96K
Open1.18
D1 Closing1.14
Amplitude3.51%
Mkt Cap6.29M
Tradable Cap6.14M
Total Shares5.47M
T/O24.17K
T/O Rate0.39%
Tradable Shares5.34M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Acurx Antibiotic Candidates Preserve Gut Microbiome in Mouse Study
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.